Iovance Biotherapeutics Inc
(NAS:IOVA)
$
9.32
-0.08 (-0.85%)
Market Cap: 2.84 Bil
Enterprise Value: 2.52 Bil
PE Ratio: 0
PB Ratio: 3.67
GF Score: 39/100 Iovance Biotherapeutics Inc at BTIG Virtual Biotechnology Conference Transcript
Aug 11, 2020 / 06:30PM GMT
Release Date Price:
$28.14
(-1.37%)
Thomas Eugene Shrader
BTIG, LLC, Research Division - MD & Healthcare Analyst
Great. Thank you, Sara. So, exciting time.
Questions & Answers
Thomas Eugene Shrader
BTIG, LLC, Research Division - MD & Healthcare Analyst
Wanted to know a little bit about your thoughts on uptake. How complex is the actual TIL delivery process? Do you have a sense of which hospitals can handle this? Are they the same CAR-T hospitals? Do you have the same sort of expected side effects? Just your thoughts around the original uptake, who's going to be comfortable in the early stages?
Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations
Sure. So we are partnering now with the leading U.S. cancer centers to prepare for the launch of lifileucel. We are targeting about 40 clinical sites at launch. A lot of these sites have had experience directly with TIL as part of our clinical studies.
And as you mentioned, because CAR-T is also a more complex process that has certainly done a good job
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot